化脓性汗腺炎：三级淋巴结构成为焦点。
Hidradenitis suppurativa: TLSs take the center stage.
作者信息
Elkins Cody, Li Chaoran
机构信息
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA; Department of Dermatology, Emory University School of Medicine, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
出版信息
Immunity. 2024 Dec 10;57(12):2712-2714. doi: 10.1016/j.immuni.2024.11.011.
Abstract
Hidradenitis suppurativa (HS) is a severe chronic inflammatory skin disease with limited response to therapy. In this issue of Immunity, Yu et al. identify skin tertiary lymphoid structures (TLSs) as primary sites for lymphocyte clonal expansion and autoantibody production, driving disease progression, and provide insight into how formation and maintenance of TLS impact therapeutic outcomes.
摘要
化脓性汗腺炎（HS）是一种严重的慢性炎症性皮肤病，对治疗反应有限。在本期《免疫》杂志中，Yu等人将皮肤三级淋巴结构（TLSs）确定为淋巴细胞克隆扩增和自身抗体产生的主要部位，这些部位推动疾病进展，并深入探讨了TLS的形成和维持如何影响治疗结果。
相似文献
1
Hidradenitis suppurativa: TLSs take the center stage.化脓性汗腺炎：三级淋巴结构成为焦点。
Immunity. 2024 Dec 10;57(12):2712-2714. doi: 10.1016/j.immuni.2024.11.011.
2
Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa.三级淋巴结构内的皮肤免疫-间充质相互作用促进化脓性汗腺炎的自身免疫发病机制。
Immunity. 2024 Dec 10;57(12):2827-2842.e5. doi: 10.1016/j.immuni.2024.11.010.
3
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa.三级淋巴结构维持化脓性汗腺炎皮肤 B 细胞的活性。
JCI Insight. 2024 Feb 8;9(3):e169870. doi: 10.1172/jci.insight.169870.
4
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.特应性皮炎、化脓性汗腺炎和白癜风的皮肤免疫及其失调。
Cell Cycle. 2020 Feb;19(3):257-267. doi: 10.1080/15384101.2019.1707455. Epub 2020 Jan 5.
5
Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?超越抗体：化脓性汗腺炎中的 B 细胞：旁观者、贡献者还是治疗靶点？
Exp Dermatol. 2020 May;29(5):509-515. doi: 10.1111/exd.14092. Epub 2020 Mar 17.
6
Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.局部用鲁索替尼的初步研究表明其对轻度化脓性汗腺炎中异质性炎症过程具有疗效并能使其减弱。
Br J Dermatol. 2025 Apr 28;192(5):845-856. doi: 10.1093/bjd/ljae495.
7
Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients.化脓性汗腺炎患者比其他皮肤病患者承受更高的全身炎症负荷。
Arch Dermatol Res. 2015 Dec;307(10):885-9. doi: 10.1007/s00403-015-1596-5. Epub 2015 Sep 9.
8
CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.表达 CD2 的固有淋巴细胞和 T 细胞是化脓性汗腺炎发病机制中的关键效应细胞。
Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2409274121. doi: 10.1073/pnas.2409274121. Epub 2024 Nov 19.
9
Hidradenitis Suppurativa Preclinical Studies: Models and Results.
Exp Dermatol. 2025 Mar;34 Suppl 1:e70089. doi: 10.1111/exd.70089.
10
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.探索 spesolimab 对中重度化脓性汗腺炎患者影响的概念验证研究：一项随机双盲安慰剂对照临床试验。
Br J Dermatol. 2024 Sep 18;191(4):508-518. doi: 10.1093/bjd/ljae144.
本文引用的文献
1
The roles of tertiary lymphoid structures in chronic diseases.三级淋巴结构在慢性疾病中的作用。
Nat Rev Nephrol. 2023 Aug;19(8):525-537. doi: 10.1038/s41581-023-00706-z. Epub 2023 Apr 12.
2
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.IL-17A 是中重度化脓性汗腺炎的一个有针对性的治疗靶点：临床前和 II 期概念验证研究的综合结果。
Exp Dermatol. 2022 Oct;31(10):1522-1532. doi: 10.1111/exd.14619. Epub 2022 Aug 19.
3
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.布罗达umab 阻断白细胞介素-17RA 可减少化脓性汗腺炎皮肤和血清中的炎症通路。
Br J Dermatol. 2022 Aug;187(2):223-233. doi: 10.1111/bjd.21060. Epub 2022 Jun 2.
4
Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages.化脓性汗腺炎中的自身抗体与疾病严重程度相关，并促进巨噬细胞中促炎细胞因子的释放。
J Invest Dermatol. 2022 Mar;142(3 Pt B):924-935. doi: 10.1016/j.jid.2021.07.187. Epub 2021 Oct 1.
5
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.浆细胞和 B 细胞在化脓性汗腺炎发病机制中的作用。
JCI Insight. 2020 Oct 2;5(19):139930. doi: 10.1172/jci.insight.139930.
6
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy.化脓性汗腺炎的免疫发病机制和抗 TNF-α 治疗反应。
JCI Insight. 2020 Oct 2;5(19):139932. doi: 10.1172/jci.insight.139932.
7
Lymph node stromal cells: cartographers of the immune system.淋巴结基质细胞：免疫系统的绘图师。
Nat Immunol. 2020 Apr;21(4):369-380. doi: 10.1038/s41590-020-0635-3. Epub 2020 Mar 23.
8
Hidradenitis suppurativa.化脓性汗腺炎。
Nat Rev Dis Primers. 2020 Mar 12;6(1):18. doi: 10.1038/s41572-020-0149-1.
9
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.阿达木单抗治疗化脓性汗腺炎的两项 3 期临床试验。
N Engl J Med. 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370.
Zotero 插件